The present invention is directed to compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

 
Web www.patentalert.com

> Methods for achieving a protective ACE2 expression level to treat kidney disease and hypertension
~ 00345